{"id":546251,"date":"2021-06-04T18:40:03","date_gmt":"2021-06-04T18:40:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546251"},"modified":"2021-06-04T18:40:03","modified_gmt":"2021-06-04T18:40:03","slug":"cholestatic-pruritus-pipeline-analysis-shows-massive-growth-potential-for-the-next-few-years","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholestatic-pruritus-pipeline-analysis-shows-massive-growth-potential-for-the-next-few-years_546251.html","title":{"rendered":"Cholestatic Pruritus pipeline analysis shows massive growth potential for the next few years"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622804443.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholestatic Pruritus pipeline analysis shows massive growth potential for the next few years\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622804443.png\" alt=\"Cholestatic Pruritus pipeline analysis shows massive growth potential for the next few years\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Cholestatic Pruritus Pipeline <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cholestatic Pruritus Pipeline Insights, 2021&#8221; report provides detailed insights into the Cholestatic Pruritus market&#8217;s current clinical development status and growth prospects. The disease summary and Cholestatic Pruritus therapy guidelines are included in a complete description of the Cholestatic Pruritus pipeline environment.\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/b90d0bc3a94b495bb8d960a55d161abc.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&#8217;s <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">&#8220;Cholestatic Pruritus Pipeline Insights, 2021&#8221;<\/a>&nbsp;<\/strong><span data-mce-mark=\"1\">report provides detailed insights into the Cholestatic Pruritus market&#8217;s current clinical development status and growth prospects. The disease summary and Cholestatic Pruritus therapy guidelines are included in a complete description of the Cholestatic Pruritus pipeline environment.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some Key Highlights from the Cholestatic Pruritus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Mirum Pharmaceuticals, GlaxoSmithKline, CymaBay Therapeutics, Cara Therapeutics, Escient Pharmaceuticals <\/strong><span>are among the notable companies who are testing their drug candidates in the Cholestatic Pruritus treatment market.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline therapy for Cholestatic Pruritus such as <\/span><strong>LUM001 (Mirum Pharmaceuticals)&nbsp;<\/strong><span>is in the pre-registration phase.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Some pipeline therapies for Cholestatic Pruritus such as <\/span><strong>GSK2330672 and Seladelpar <\/strong><span>are in the Phase III of development while pipeline therapy like <\/span><span>Korsuva <\/span><span>is in Phase II of clinical trials.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pipeline therapy such as <\/span><strong>EP 547 <\/strong><span>is still in the early stage of development i.e. Phase I of clinical trials for Cholestatic Pruritus.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For more information request sample @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cholestatic-pruritus-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cholestatic Pruritus Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus: Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Cholestasis is a reduction in bile flow caused by decreased hepatocyte secretion or obstruction of bile flow through intra- or extrahepatic bile ducts. This bile secretion problem occurs somewhere between the liver cells that make bile and the duodenum (the first segment of the small intestine).<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Furthermore, both intrahepatic cholestasis and extrahepatic biliary blockage can cause pruritus. Primary Biliary Cirrhosis (PBC), cholestasis during pregnancy (pruritus gravidarum), drug-induced cholestasis, and viral hepatitis are all intrahepatic cholestasis processes linked to pruritus.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>GSK2330672: GlaxoSmithKline<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>GSK2330672 is a human IBAT selective inhibitor that is designed to be a non-absorbable drug that is limited to the gastrointestinal (GI) tract. The company has completed Phase II of clinical development, and phase III trials are currently underway.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Research and Development in the Cholestatic Pruritus Pipeline Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase III<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT04167358: <\/strong><span>GlaxoSmithKline began a study called &#8220;Long-term Safety and Tolerability Study with Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis&#8221; in July 2020. The trial is presently recruiting volunteers, with a target participation of 75 people, and it is set to end in December 2024.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>LUM001: Mirum Pharmaceuticals<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>GSK2330672: GlaxoSmithKline<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Seladelpar: CymaBay Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Korsuva: Cara Therapeutics<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>EP 547: Escient Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Learn more about Cholestatic Pruritus @ <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cholestatic Pruritus Pipeline Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Monotherapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Combination Therapy<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Discovery<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pre-Clinical<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase I<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase II<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Phase III<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Pre-registration<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Inhalation<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Intravenous<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Oral<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Subcutaneous<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Small Molecule<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Stem Cell Therapy<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Gene Therapy<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Immune System<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Multiple Kinase<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Protease<\/span><\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Protease Inhibitors<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Immunomodulatory<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Multiple Kinase Inhibitors<\/span><\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong><span> Global<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Key Players: <\/strong><span>Mirum Pharmaceuticals, GlaxoSmithKline, CymaBay Therapeutics, Cara Therapeutics, Escient Pharmaceuticals, among others<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Pipeline Therapies: <\/strong><span>LUM001, GSK2330672, Seladelpar, Korsuva, EP 547, and others<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"110\" \/>\n<col width=\"514\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><span>1.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>2.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Executive Summary<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>3.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus: Overview<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>4.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus- Analytical Perspective In-depth Commercial Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>5.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Pipeline Therapeutics<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>6.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Late Stage Products (Pre-Registration)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>7.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Late Stage Products (Phase III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>8.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Mid Stage Products (Phase II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>9.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Early Stage Products (Phase&nbsp; I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>10.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Therapeutic Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>11.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>12.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>13.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>14.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>15.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus- Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>16.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus- Market Drivers and Barriers<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>17.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus- Future Perspectives and Conclusion<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>18.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Cholestatic Pruritus Analyst Views<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><span>19.<\/span><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><span>Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For rich insights into Healthcare and Pharmaceutical News, visit <\/span><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Cholestatic Pruritus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>What are the treatment options for Cholestatic Pruritus?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many companies are working on Cholestatic Pruritus treatments?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Which of these companies&#8217; medicines is the most widely used?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many Cholestatic Pruritus medicines has each company generated in total?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many innovative therapies for Cholestatic Pruritus are being developed in the early, mid, and late stages?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>How many of the drugs under development can be used alone or in combination with other treatments?<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>What are the most important industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises that will affect Cholestatic Pruritus?<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/primary-biliary-cholangitis-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Primary Biliary Cholangitis Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Get comprehensive analysis of <\/span><span>Primary Biliary Cholangitis<\/span><span> pipeline therapies and key companies including <\/span><strong>Genfit, CymaBay Therapeutics, Mirum Pharmaceuticals, Gilead Sciences, Eli Lilly and Company, Future Medicine,<\/strong><span> among others.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholestatic-pruritus-pipeline-analysis-shows-massive-growth-potential-for-the-next-few-years\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholestatic-pruritus-pipeline-analysis-shows-massive-growth-potential-for-the-next-few-years\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cholestatic Pruritus Pipeline DelveInsight&#8217;s &#8220;Cholestatic Pruritus Pipeline Insights, 2021&#8221; report provides detailed insights into the Cholestatic Pruritus market&#8217;s current clinical development status and growth prospects. The disease summary and Cholestatic Pruritus therapy guidelines are included in a complete description of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholestatic-pruritus-pipeline-analysis-shows-massive-growth-potential-for-the-next-few-years_546251.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-546251","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546251"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546251\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}